...
首页> 外文期刊>Helicobacter >Intranasal CpG-Oligodeoxynucleotide is a potent adjuvant of vaccine against Helicobacter pylori, and t helper 1 type response and interferon-gamma correlate with the protection
【24h】

Intranasal CpG-Oligodeoxynucleotide is a potent adjuvant of vaccine against Helicobacter pylori, and t helper 1 type response and interferon-gamma correlate with the protection

机译:鼻内CpG-寡脱氧核苷酸是针对幽门螺杆菌疫苗的有效佐剂,其辅助1型反应和干扰素-γ与保护相关

获取原文
获取原文并翻译 | 示例
           

摘要

Background. Although a series of vaccines against Helicobacter pylori have emerged in the past 10 years, the mechanism involved in their protective effect is yet to be elucidated, and more effective vaccine adjuvants remain to be developed. In this study, CpG-oligodeoxynucleotide (CpG-ODN) was investigated as a new candidate for a H. pylori vaccine adjuvant. Furthermore, the role of T helper 1 (Th1) type response and interferon (IFN)-gamma in the protective immunity was explored.Methods. C57BL/6 mice and IFN-gamma knockout mice were intranasally or orally immunized with H. pylori whole cell sonicate (WCS)/CpG-ODN and challenged with different doses [5 x 10(8) and 5 x 10(6) colony-forming units (CFU)] of H. pylori. The protective effect was assessed as the percentage of noninfected mice. The responsive antibodies and cytokines were analyzed using an enzyme-linked immunosorbent assay (ELISA) and flow cytometry.Results. The prevention rates against H. pylori infection in mice intranasally immunized with WCS plus CpG-ODN were dramatically higher than those in sham-immunized mice (70% vs. 0%, challenged with 5 x 10(8) CFU H. pylori; 90% vs. 20%, challenged with 5 x 10(6) CFU H. pylori). Significantly higher levels of immunoglobulin G2a (IgG2a) and IFN-gamma were detected in the mice immunized with WCS/CpG than in sham-immunized controls. However, vaccination failed to effectively protect IFN-gamma knockout mice challenged with H. pylori.Conclusions. CpG-ODN given intranasally is a potent adjuvant for development of a H. pylori vaccine. Th1-type response and IFN-gamma are involved in the protection.
机译:背景。尽管在过去的十年中已经出现了一系列针对幽门螺杆菌的疫苗,但是尚未阐明其保护作用的机制,还有待开发更有效的疫苗佐剂。在这项研究中,研究了CpG-寡脱氧核苷酸(CpG-ODN)作为幽门螺杆菌疫苗佐剂的新候选药物。此外,还探讨了T辅助1(Th1)型反应和干扰素(IFN)-γ在保护性免疫中的作用。用幽门螺杆菌全细胞超声(WCS)/ CpG-ODN鼻内或口服免疫C57BL / 6小鼠和IFN-γ敲除小鼠,并用不同剂量攻击[5 x 10(8)和5 x 10(6)菌落-幽门螺杆菌的形成单位(CFU)。以未感染小鼠的百分比评估保护作用。使用酶联免疫吸附测定(ELISA)和流式细胞仪分析反应性抗体和细胞因子。用WCS加CpG-ODN鼻内免疫的小鼠对幽门螺杆菌感染的预防率显着高于假免疫的小鼠(70%vs. 0%,用5 x 10(8)CFU幽门螺杆菌攻击; 90) %与20%,用5 x 10(6)CFU幽门螺杆菌攻击)。与假免疫对照相比,在用WCS / CpG免疫的小鼠中检测到的免疫球蛋白G2a(IgG2a)和IFN-γ明显更高。然而,疫苗接种未能有效保护受到幽门螺杆菌攻击的IFN-γ基因敲除小鼠。鼻内给予的CpG-ODN是开发幽门螺杆菌疫苗的有效佐剂。 Th1型应答和IFN-γ参与保护。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号